Skip to main content

Table 2 Next generation sequencing panel and mutation frequency

From: Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias

Gene

Criteria for selection for gene panel

Hot spot

Frequency of mutation in PCD

Frequency of mutation in present study

%

Total number of cases

PCD type

KRAS

Potentially druggable

Exon 2;3

Up to 30%

24

24%

22

MM

NRAS

Potentially druggable

Exon 2;3

Up to 30%

14

16%

14

MM

DIS3

Prognosis

Whole gene

Up to 1%

14

12%

11

MM MGUS

TENT5C (FAM46C)

Prognosis

Whole gene

Up to 4%

13

12%

11

MM

MGUS

TP53

Prognosis

Whole gene

Up to 20%

9

10%

9

MM

BRAF

Potentially druggable

Exon 11; 15

Up to 9% in rr MM*

9

10%

9

MM

TRAF3

Frequently mutated

Whole gene

Up to 4%

8

7%

6

MM

FGFR3

Prognosis/potentially druggable

Whole

Up to 1.5%

4

6%

4

MM

IDH1

Potentially druggable

Exon 4

 

3

3%

3

MM

ALA

EGR1

Frequently mutated

Whole gene

Up to 1%

2

2%

2

MM

IRF4

Prognosis

Exon 3

Up to 3%

2

2%

2

MM

CCND1

Prognosis/potentially druggable

Whole gene

Up to 3%

0

no

0

no

PRDM1

Frequently mutated

Whole gene

Up to

0

no

0

no

IDH2

Potentially druggable

Exon 4

 

0

no

0

no